A small dose of greed can be a good thing for orthopedic company leaders... but excessive greed can be problematic.
For instance, greed can get in the way during M&A negotiations.
Greed can distort what a company is actually worth. Often, CEOs, boards and shareholders have an over-inflated viewpoint regarding the value of their company.
As part of the Arthrex/Corin story, we learned that Arthrex offered Corin $1B years earlier, Corin walked out, then agreed to Arthrex's $330M offer this year. Read - First look at the Arthrex acquisition of Corin
Check your greed with negotiating early acqu...
